Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Arthritis, Rheumatoid | 7 | 2021 | 2043 | 0.99 | Why? |
| Interleukin-12 | 1 | 2021 | 156 | 0.82 | Why? |
| Peripheral Nerve Injuries | 1 | 2021 | 114 | 0.80 | Why? |
| Sexual Dysfunctions, Psychological | 1 | 2018 | 37 | 0.74 | Why? |
| Leprosy | 1 | 2021 | 142 | 0.74 | Why? |
| Antirheumatic Agents | 6 | 2021 | 3023 | 0.52 | Why? |
| Pensions | 1 | 2018 | 11 | 0.38 | Why? |
| Insurance, Disability | 1 | 2018 | 11 | 0.38 | Why? |
| Yellow Fever Vaccine | 2 | 2019 | 198 | 0.32 | Why? |
| Fatigue | 1 | 2017 | 2479 | 0.31 | Why? |
| Fibromyalgia | 1 | 2018 | 174 | 0.30 | Why? |
| Yellow Fever | 2 | 2019 | 231 | 0.29 | Why? |
| Brazil | 9 | 2021 | 12582 | 0.28 | Why? |
| Psoriasis | 1 | 2018 | 1739 | 0.27 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.24 | Why? |
| Leprosy, Borderline | 1 | 2020 | 10 | 0.22 | Why? |
| Lymphadenitis | 1 | 2020 | 53 | 0.21 | Why? |
| Pyrroles | 2 | 2020 | 292 | 0.19 | Why? |
| Chagas Disease | 1 | 2020 | 155 | 0.18 | Why? |
| Sulfasalazine | 1 | 2018 | 87 | 0.18 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.18 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.17 | Why? |
| Piperidines | 2 | 2020 | 795 | 0.15 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.14 | Why? |
| Immune System Diseases | 1 | 2019 | 410 | 0.14 | Why? |
| Methotrexate | 1 | 2018 | 471 | 0.13 | Why? |
| Pyrimidines | 2 | 2020 | 1557 | 0.13 | Why? |
| Disability Evaluation | 1 | 2017 | 671 | 0.13 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.13 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.11 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2020 | 1380 | 0.09 | Why? |
| Gene Expression Regulation | 1 | 2021 | 4020 | 0.09 | Why? |
| Glucocorticoids | 2 | 2018 | 4431 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Rheumatology | 1 | 2018 | 1213 | 0.09 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.07 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.07 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Rheumatic Diseases | 1 | 2021 | 2675 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Registries | 2 | 2021 | 12327 | 0.07 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.06 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.06 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.06 | Why? |
| Female | 10 | 2021 | 380317 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.06 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.06 | Why? |
| Adult | 6 | 2021 | 244371 | 0.06 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.06 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.05 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2019 | 6331 | 0.05 | Why? |
| Humans | 15 | 2021 | 930598 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Aged | 6 | 2021 | 215776 | 0.05 | Why? |
| Lupus Erythematosus, Cutaneous | 1 | 2020 | 104 | 0.05 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.05 | Why? |
| Male | 8 | 2021 | 367725 | 0.05 | Why? |
| Contraindications, Drug | 1 | 2019 | 281 | 0.04 | Why? |
| Platelet Aggregation | 1 | 2020 | 318 | 0.04 | Why? |
| Young Adult | 3 | 2018 | 93724 | 0.04 | Why? |
| Sjogren's Syndrome | 1 | 2020 | 284 | 0.04 | Why? |
| Polypharmacy | 1 | 2019 | 347 | 0.04 | Why? |
| Inflammation | 1 | 2019 | 13255 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Glucose | 1 | 2020 | 573 | 0.04 | Why? |
| Drug Eruptions | 1 | 2020 | 319 | 0.04 | Why? |
| Retinal Diseases | 1 | 2020 | 441 | 0.04 | Why? |
| Delphi Technique | 1 | 2019 | 1257 | 0.03 | Why? |
| Pregnancy | 2 | 2021 | 23879 | 0.03 | Why? |
| Symptom Assessment | 1 | 2018 | 4967 | 0.03 | Why? |
| Antiphospholipid Syndrome | 1 | 2020 | 533 | 0.03 | Why? |
| Uganda | 1 | 2017 | 1057 | 0.03 | Why? |
| Biological Products | 1 | 2018 | 2331 | 0.03 | Why? |
| Lipids | 1 | 2020 | 1079 | 0.03 | Why? |
| Renal Insufficiency | 1 | 2020 | 810 | 0.03 | Why? |
| Drug Interactions | 1 | 2020 | 1653 | 0.03 | Why? |
| Vaccines, Attenuated | 1 | 2017 | 952 | 0.03 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.03 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.03 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.03 | Why? |
| BCG Vaccine | 1 | 2020 | 1137 | 0.03 | Why? |
| Family Characteristics | 1 | 2020 | 2551 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.02 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.02 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Emergency Medical Services | 1 | 2021 | 3557 | 0.02 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.02 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.02 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Retrospective Studies | 1 | 2018 | 105322 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Comorbidity | 1 | 2019 | 34796 | 0.01 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.00 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.00 | Why? |